Spire Healthcare Group plc
("Spire Healthcare", "the Company" or "the Group")
NHS COVID-19 support
13 March 2020
Spire Healthcare (LSE: SPI), a leading UK independent hospital group, today announces that following a meeting with NHS England and representatives from across the private sector to discuss future COVID-19 planning, Spire Healthcare has been asked for, and has offered, its support to the NHS during this challenging time.
The exact nature, extent and the timing of this support is yet to be determined; in the meantime, we continue to offer a full service to our patients. We will update the market when further information is available.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further information please contact:
Spire Healthcare Cora McCallum, Head of Investor Relations |
+44 (0)20 7427 9169 |
Instinctif Partners Guy Scarborough Damian Reece |
+44 (0)7917 178 920 +44 (0)7931 598 593 |
Registered Office and Head Office:
Spire Healthcare Group plc
3 Dorset Rise
London
EC4Y 8EN
Registered number 09084066
About Spire Healthcare
Spire Healthcare is a leading independent hospital group in the United Kingdom, with 39 private hospitals and 8 clinics across England, Wales and Scotland.
Working in partnership with around 7,300 experienced consultants, Spire Healthcare delivered tailored, personalised care to approximately 810,000 in-patients and daycase patients in 2019, and is the leading private provider, by volume, of knee and hip operations in the United Kingdom.
The Group's well located and scalable hospitals have delivered successful and award-winning clinical outcomes, positioning the Group well with patients, consultants, the NHS, GPs and Private Medical Insurance ("PMI") providers. 85% of Spire Healthcare's hospitals are rated Good or Outstanding by the CQC (or the equivalent in Scotland and Wales).
Spire treats patients through a variety of routes including PMI, Self-pay and the NHS, providing the Group with diversified access to the expected growth opportunities in the UK healthcare market, which faces significant supply challenges as a result of NHS budget constraints and increasing demand from a growing population with longer life expectancy.
